BioCentury
ARTICLE | Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

NIH testing mAbs from Vir, Brii in hospitalized COVID-19 patients

December 19, 2020 4:34 AM UTC

NIH has added two investigational mAb therapies to its ACTIV-3 Phase III master protocol of hospitalized COVID-19 patients, hoping to succeed in a setting where two other mAbs failed.

Headlines about record-breaking death statistics in the U.S., as well as widespread failure to deploy mAbs that have been authorized for outpatient use, point to the urgent need for safe, effective treatments that can save the lives of hospitalized COVID-19 patients. ...